KLK3 and benign prostatic hyperplasia: Comparing the level of decrease in the final PSA after the 7 days treatment suggests that AFAL (200 mg/kg body weight) exhibited a similar ameliorative effect as dutasteride on the induced BPH, possibly through 5α-reductase inhibitory activity among other mechanisms.